•  
  •  
  •  
  •  

2025-08-28 23:30:27

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
  • HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
  • Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
  • SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
  • Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd

Keywords Selected:  GlenmarkPharmaceuticals

Stock Report

  • Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial
  • Ichnos Glenmark Innovation announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
  • Ichnos Glenmark Innovation and AbbVie announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
  • Glenmark Pharmaceuticals Launches TEVIMBRA® in India
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies
  • Ichnos Glenmark Innovation receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
  • Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
  • Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)
  • Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
  • Glenmark Pharma expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India
  • Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful - OTC
  • Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules
  • Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL
  • Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004%
  • U.S. FDA inspection at Glenmark Pharmaceuticals Ltd's Facility at Chhatrapati Sambhaji Nagar, India
  • Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% OTC
  • Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg
  • Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg - OTC
  • Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg
  • Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023‐24
  • Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India

Latest Post

  • Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
  • HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
  • Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
  • SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
  • Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024